Welcome
Support Centre
09 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Magnetic resonance imaging (MRI) fluoroscopy for imaging childhood vesicoureteric reflux
ISRCTN ISRCTN98320102
ClinicalTrials.gov identifier
Public title Magnetic resonance imaging (MRI) fluoroscopy for imaging childhood vesicoureteric reflux
Scientific title Magnetic resonance imaging (MRI) replacement of x-ray fluoroscopy in paediatric imaging: an investigation of vesicoureteric reflux
Acronym N/A
Serial number at source 6149
Study hypothesis X-ray fluoroscopy is widely used for diagnosing suspected serious childhood abnormalities such as urinary tract abnormalities, despite the induced solid malignancy risk secondary to ionising radiation exposure. Magnetic resonance imaging (MRI) is considered safer than X-rays, but fluoroscopy-like MRI techniques have not yet been developed for paediatric applications, where the avoidance of ionising radiation would be of great benefit. Development requires the integration and adaptation of MR technologies to support the study of small children in the relatively hostile environment of an MR system, and evidence that similar results to X-ray fluoroscopy are achievable.

Aims:
1. To develop robust MR applications based on recently developed MR technology for childhood abnormalities of the renal tract (vesico-ureteric reflux and posterior urethral valves).
2. To evaluate the technical and diagnostic performance of the MR technique by direct comparison with the established X-ray fluoroscopy based techniques.
Ethics approval Cambridgeshire 3 Research Ethics Committee approved on the 26th June 2008 (ref: 08/H0306/39)
Study design Single centre non-randomised observational diagnosis and validation of investigative process trial
Countries of recruitment United Kingdom
Disease/condition/study domain Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Paediatrics
Participants - inclusion criteria 1. All children (usually boys) between the ages of 0 and 3 years referred for direct micturating cysto-urethrography (MCUG)
2. All children with hydronephrosis diagnosed antenatally on foetal ultrasound
3. Age range: 0 days - 3 years, male and female
Participants - exclusion criteria 1. Usual MR exclusion criteria will apply, but are highly unlikely in this age group. The include pregnancy, claustrophobia, cardiac pacemakers, metallic implants, cardiac defibrillator implants, aneurysym clips or metallic heart valves, and cochlear or inner ear implants. These exclusion criteria clearly apply to all people within the vicienity of the MRI scanner, and therefore apply equally to the parents/guardians in this study.
2. Previous reaction to the relevant x-ray or MRI contrast medium (including gadolinium)
3. Congenital abnormalities that make X-ray fluoroscopy of MR fluoroscopy impractical
Anticipated start date 01/09/2008
Anticipated end date 01/09/2011
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants Planned sample size: 50
Interventions All patients volunteering for this study will undergo conventional XR fluoroscopy as per standard care, followed by an additional MRI examination. Data collection involves completion of demographic proformas, parent questionnaires, and real-time acquisition of radiological images which will be assessed and stored for retrospective analysis. The two examinations are expected to take place within 24 hours of each other. The conventional X-ray studies will be reported immediately following normal practice and allowing for clinical management and decision making. Both the XR and MRI studies will be reported for the presence/absence of posterior urethral ballooning during voiding and the presence and grade of any VUR using the conventional established grading scheme. In each case the person supervising and reporting the respective studies will not be aware of the results of the other investigation.

There is no follow-up as part of this study, but patients will be treated as per standard care on the basis of the results from their XR fluoroscopy examination.
Primary outcome measure(s) The ability of the MR fluoroscopy examination to accurately detect:
1. Significant grade VUR likely to alter clinical management
2. The presence of posterior urethral ballooning

Assessed at the time of the intervention
Secondary outcome measure(s) Assessed at the time of the intervention:
1. Image quality
2. Artifacts
Sources of funding National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) programme
Trial website
Publications
Contact name Ms  Wendy  Phillips
  Address Radiology, Box 162
Hills Road
  City/town Cambridge
  Zip/Postcode CB2 0QQ
  Country United Kingdom
  Email wendyphillips@addenbrookes.nhs.uk
Sponsor Cambridge University Hospitals NHS Foundation Trust (UK)
  Address Addenbrookes Hospital
Hills Road
  City/town Cambridge
  Zip/Postcode CB2 0QQ
  Country United Kingdom
  Sponsor website: http://www.cuh.org.uk/addenbrookes/addenbrookes_index.html
Date applied 07/07/2010
Last edited 26/07/2010
Date ISRCTN assigned 07/07/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central